azacitidine 200 mg tablet

A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Phase 2, open-label, single-arm rollover study to evaluate long-term Safety in subjects who participated in other Celgene sponsored CC-486 (oral Azacitidine) clinical trials in Hematological disorders